Interleukin-10 blunts the human inflammatory response to lipopolysaccharide without affecting the cardiovascular response.

Objective: The objective of this study was to assess the efficacy of variations in dose and timing of administration of recombinant human IL-10 (rhIL-10) on inflammatory and cardiovascular responses in a human endotoxemia model of sepsis.

Design: The authors conducted a randomized, placebo-controlled, double-blind trial.

Setting: The study was conducted in a procedure room of an intensive-care unit.